WuXi Biologics (Cayman) Inc. (2269.HK)
| Previous close | 10.660 |
| Open | 10.660 |
| Bid | 10.540 x 0 |
| Ask | 10.560 x 0 |
| Day's range | 10.500 - 10.840 |
| 52-week range | 10.500 - 52.450 |
| Volume | |
| Avg. volume | 56,091,774 |
| Market cap | 43.838B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | 12.72 |
| EPS (TTM) | 0.830 |
| Earnings date | 21 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.99 |
PR NewswireWuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year the company has been included in the Index for its outstanding sustainability performance.
South China Morning PostUS House committee moves quickly to approve bill limiting business with Chinese biotech firms
Bipartisan legislation that would restrict US business with world-leading Chinese biotech companies and their subsidiaries was approved by a House of Representatives committee on Wednesday. The House Committee on Oversight and Accountability passed the bill 40-1. To become law, the bill must pass the full House and Senate, then be signed by the president. The bill, introduced on Friday, would prevent federal agencies from contracting with five Chinese biotech companies - BGI Group, MGI, Complete
PR NewswireWuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today published its 2023 Environmental, Social and Governance (ESG) Report, highlighting the company's substantial progress in advancing sustainable development.
